Oncternal Therapeutics Inc - Asset Resilience Ratio
Oncternal Therapeutics Inc (ONCT) has an Asset Resilience Ratio of 9.61% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ONCT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2023)
This chart shows how Oncternal Therapeutics Inc's Asset Resilience Ratio has changed over time. See ONCT equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Oncternal Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Oncternal Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 9.61% |
| Total Liquid Assets | $1.50 Million | 9.61% |
Asset Resilience Insights
- Limited Liquidity: Oncternal Therapeutics Inc maintains only 9.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oncternal Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Oncternal Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Oncternal Therapeutics Inc (2007–2023)
The table below shows the annual Asset Resilience Ratio data for Oncternal Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 75.03% | $27.56 Million | $36.73 Million | +36.31pp |
| 2022-12-31 | 38.72% | $26.58 Million | $68.65 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $93.58 Million | -- |
| 2018-12-31 | 0.64% | $200.00K | $31.32 Million | -60.10pp |
| 2017-12-31 | 60.74% | $28.08 Million | $46.24 Million | +7.85pp |
| 2016-12-31 | 52.89% | $12.96 Million | $24.50 Million | +5.44pp |
| 2015-12-31 | 47.45% | $15.20 Million | $32.03 Million | -14.57pp |
| 2014-12-31 | 62.02% | $31.41 Million | $50.65 Million | +60.74pp |
| 2013-12-31 | 1.28% | $200.00K | $15.61 Million | -12.64pp |
| 2012-12-31 | 13.92% | $8.04 Million | $57.77 Million | +0.25pp |
| 2011-12-31 | 13.68% | $10.70 Million | $78.18 Million | +12.98pp |
| 2010-12-31 | 0.70% | $450.00K | $64.25 Million | -14.59pp |
| 2009-12-31 | 15.29% | $8.82 Million | $57.72 Million | +13.29pp |
| 2008-12-31 | 2.00% | $2.16 Million | $108.11 Million | -4.15pp |
| 2007-12-31 | 6.14% | $9.81 Million | $159.73 Million | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more